Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 6.03% is 42% above its 5-year average of 4.25%, around the middle of its 5-year range (0.13%–16.98%).
As of the fiscal period ended Tuesday, June 30, 2026. 24.62% below its 12-month average of 8.01%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 6.03%.
DEBT TO ASSETS RATIO
6.03%
DEBT TO ASSETS RATIO AVG TTM
8.01%
DEBT TO ASSETS RATIO AVG 3Y
6.22%
DEBT TO ASSETS RATIO AVG 5Y
4.25%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-24.62%
CURRENT VS 3Y AVG
-3.01%
CURRENT VS 5Y AVG
+42.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 584 covered companies
CURRENT VS SECTOR MEDIAN
+5934.70%
vs the sector median at left
ALX Oncology Holdings Inc.
Market Cap
$155.42M
Debt to Assets Ratio
6.03%
TTM Avg
8.01%
3Y Avg
6.22%
5Y Avg
4.25%
Market Cap
$156.62M
Debt to Assets Ratio
0.89%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$156.15M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.53M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$151.58M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$162.23M
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.54M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $155.42M | 6.03% | 8.01% | 6.22% | 4.25% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | 0.89% | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $156.15M | 0.00% | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $157.84M | 0.06% | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $154.53M | 0.00% | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $151.66M | 0.60% | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | 0.00% | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $162.23M | 0.20% | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | 0.00% | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $147.21M | 0.00% | N/A | N/A | N/A |
Debt/Assets
6.0%
Debt/Equity
0.07
Current Ratio
9.71
Interest Coverage
-64.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 6.03% |
| 2026-03-31 | 2.93% |
| 2025-12-31 | 8.84% |
| 2025-09-30 | 5.26% |
| 2025-06-30 | 16.98% |
| 2025-03-31 | 8.25% |
| 2024-12-31 | 6.70% |
| 2024-09-30 | 5.30% |
| 2024-06-30 | 8.14% |
| 2024-03-31 | 7.92% |
| 2023-12-31 | 7.09% |
| 2023-09-30 | 4.35% |
| 2023-06-30 | 3.87% |
| 2023-03-31 | 3.74% |
| 2022-12-31 | 3.40% |
| 2022-09-30 | 2.08% |
| 2022-06-30 | 0.31% |
| 2022-03-31 | 0.28% |
| 2021-12-31 | 0.20% |
| 2021-09-30 | 0.18% |
| 2021-06-30 | 0.13% |
| 2021-03-31 | 0.05% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 2.19% |
| 2020-06-30 | 5.47% |
| 2020-03-31 | 5.10% |
| 2019-12-31 | 50.78% |
